Hepatoprotection and lethality rescue by histone deacetylase inhibitor valproic acid in fatal hemorrhagic shock

Journal of Trauma - Injury, Infection and Critical Care

Volumn 65, Issue 3, 2008, Pages 554-564

  Gonzales, Earl R ^a   Chen, Huazhen ^a   Munuve, Richard M ^a   Mehrani, Tina ^a   Nadel, Amal ^a   Koustova, Elena ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Hemorrhage; Histone deacetylase; Hyperacetylation; Survival; Valproate

Indexed keywords

2 METHYL 2 PENTENOIC ACID; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUTATHIONE TRANSFERASE ALPHA; HISTONE H2A; HISTONE H3; HISTONE H4; LACTATE DEHYDROGENASE; LACTIC ACID; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VALPROIC ACID; VALPROIC ACID DERIVATIVE; ENZYME INHIBITOR; HISTONE; HISTONE DEACETYLASE;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD VOLUME; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HEMORRHAGIC SHOCK; LETHALITY; LIVER PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL TIME; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; LIVER; METABOLISM; PATHOLOGY; WISTAR KYOTO RAT;

ACETYLATION; ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HISTONE DEACETYLASES; HISTONES; LIVER; MALE; RATS; RATS, INBRED WKY; SHOCK, HEMORRHAGIC; VALPROIC ACID;

EID: 67650305179     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e31818233ef     Document Type: Article

References (38)

1. Henao FJ, Daes JE. Risk factors for multiorgan failure: a case-control study. J Trauma. 1991;31:74-80.
2. Helling TS. The liver and hemorrhagic shock. J Am Coll Surg. 2005; 201:774-783.
3. Strassburg CP. Gastrointestinal disorders of the critically ill. Shock liver. Best Pract Res Clin Gastroenterol. 2003;17:369-381.
4. van Way CW, Dhar A, Morrison D. Hemorrhagic shock: a new look at an old problem. Mol Med. 2003;100:518-523.
5. Khochbin S, Wolffe AP. The origin and utility of histone deacetylases. FEBS Lett. 1997;419:157-160.
6. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 2000;19:1176-1179.
7. Alam HB, Stegalkina S, Rhee P, Koustova E. cDNA array analysis of gene expression following hemorrhagic shock and resuscitation in rats. Resuscitation. 2002;54:195-206.
8. Sundar SV, Li YY, Rollwagen FM, Maheshwari RK. Hemorrhagic shock induces differential gene expression and apoptosis in mouse liver. Biochem Biophys Res Commun. 2005;332:688-696.
9. Berger SL. Gene activation by histone and factor acetyltransferases. Curr Opin Cell Biol. 1999;11:336-341.
10. Blaheta RA, Cinatl J Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev. 2002;22:492-511.
11. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein, PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001; 276:36734-36741.
12. de Sarno P, Li X, Jope RS. Regulation of akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 2002;43:1158-1164.
13. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J Neurochem. 2004;89:1358-1367.
14. Lee HB, Blaufox MD. Blood volume in the rat. J Nucl Med. 1985; 26:72-76.
15. Cerovic O, Golubovic V, Spec-Marn A, Kremzar B, Vidmar G. Relationship between injury severity and lactate levels in severely injured patients. Intensive Care Med. 2003;29:1300-1305.
16. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403:41-45.
17. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737-749.
18. Lin T, Alam HB, Chen H, et al. Cardiac histones are substrates of histone deacetylase activity in hemorrhagic shock and resuscitation. Surgery. 2006;139:365-376.
19. Chang KT, Min KT. Regulation of lifespan by histone deacetylase. Ageing Res Rev. 2002;1:313-326.
20. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000;92:1210-1216.
21. Eyal S, Yagen B, Shimshoni J, Bialer M. Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem Pharmacol. 2005; 69:1501-1508.
22. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia. 2004;45:737-744.
23. Isoherranen N, Yagen B, Bialer M. New CNS-active drugs which are second-generation valproic acid: can they lead to the development of a magic bullet? Curr Opin Neurol. 2003;16:203-211.
24. Gurvich N, Tsygankova OM, Meikoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 2004;64:1079-1086.
25. Jeong MR, Hashimoto R, Senatorov VV, et al. Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition. FEBS Lett. 2003;542:74-78.
26. Kim S, Benguria A, Lai CY, Jazwinski SM. Modulation of life-span by histone deacetylase genes in Saccharomyces cerevisiae. Mol Biol Cell. 1999;10:3125-3156.
27. Runwdlett SE, Carmen AA, Kobayashi R, Bavykin S, Turner BM, Grunstein M. HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci USA. 1996;93:14503-14508.
28. Kang H, Benzer S, Min KT. Life extension in Drosophila by feeding a drug. Proc Natl Acad Sci USA. 2002;99:838-843.
29. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001;413:739-743.
30. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature. 2002;403:795-800.
31. Gonzales E, Chen H, Munuve R, et al. Valproic acid prevents hemorrhage-associated lethality and affects the acetylation pattern of cardiac histones. Shock. 2006;25:395-401.
32. Blotnik S, Bergman F, Bialer M. Disposition of valpromide, valproic acid and valnoctomide in the brain, liver, plasma and urine of rats. Drug Metab Dispos. 1996;24:560-564.
33. Armeanu S, Pathil A, Venturalli S, et al. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357. J Hepatol. 2005;42:210-217.
34. van Wagensveld BA, Scheepers JJ, van Gulik TM, et al. Alpha glutathione S-transferase as novel parameter for hepatocellular damage in the isolated perfused rat liver. Transplant Proc. 1997; 29:3449-3451.
35. Dreifuss FE, Santilli N, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology. 1987;37:379-385.
36. Glaser KB, Li J, Pease LJ. Differential protein acetylation induced by novel histone deacetylase inhibitors. Biochem Biophys Res Commun. 2004;325:683-690.
37. Fu Q, McKnight RA, Yu X, Wang L, Callaway CW, Lane RH. Uteroplacental insufficiency induces site-specific changes in histone H3 covalent modifications and affect DNA-histone H3 positioning in day 0 IUGR rat liver. Physiol Genomics. 2004;20:108-116.
38. Iizuka M, Smith MM. Functional consequences of histone modifications. Cur Opin Genetics Devel. 2003;13:154-160.